Epstein Secrets

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

r animals for resistance to infectious diseases and to act as transplantation donors for major organs (initially kidneys) to humans. Co-founded with Prashant Mali and Luhan Yang. Already has a couple of contracts and a some rented lab space. 3) Sensor-selector technology for optimizing commercial production o

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

r animals for resistance to infectious diseases and to act as transplantation donors for major organs (initially kidneys) to humans. Co-founded with Prashant Mali and Luhan Yang. Already has a couple of contracts and a some rented lab space. 3) Sensor-selector technology for optimizing commercial production o

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

r animals for resistance to infectious diseases and to act as transplantation donors for major organs (initially kidneys) to humans. Co-founded with Prashant Mali and EFTA_R1_00488322 EFTA01980272 Luhan Yang. Already has a couple of contracts and a some rented lab space. 3) Sensor-selector technology for o

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

r animals for resistance to infectious diseases and to act as transplantation donors for major organs (initially kidneys) to humans. Co-founded with Prashant Mali and Luhan Yang. Already has a couple of contracts and a some rented lab space. 3) Sensor-selector technology for optimizing commercial production o